SCLXW Stock: Scilex Holding Company Stock Price, Analysis & Insights
Get live SCLXW stock price $0.16, comprehensive Scilex Holding Company stock analysis, charts, news, and expert forecast. Real-time SCLXW stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-on...
Company Information
- CEO
- Henry H. Ji
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 115
Contact Information
- Address
- 960 San Antonio Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.71)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Scilex Holding Company shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Scilex Holding Company
- ⚠Investors should consider how Scilex Holding Company fits within their overall portfolio allocation
Market Cap
70.38M
Beta
1.71
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare SCLXW with peer companies:
- Price
- $7.31+1.09% (1D)
- Market cap
- 68.34M
- Price
- $3.32+2.11% (1D)
- Market cap
- 124.99M
- Price
- $23.48+0.00% (1D)
- Market cap
- 151.73M
- Price
- $2.25+2.67% (1D)
- Market cap
- 20.83M
- Price
- $9.76-2.40% (1D)
- Market cap
- 49.18M
- Price
- $1.64+0.00% (1D)
- Market cap
- 69.95M
- Price
- $0.74-0.93% (1D)
- Market cap
- 25.33M
- Price
- $3.76-0.00% (1D)
- Market cap
- 64.99M
- Price
- $3.03-2.64% (1D)
- Market cap
- 26.10M
- Price
- $144.19+0.28% (1D)
- Market cap
- 30.65B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
60/100 ⭐⭐⭐⭐
- Overall
- -1.4%
- NYSE
- -0.6%
- NASDAQ
- -2.2%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.2% | +1.6% | +1.7% | 19.1 | 100/100⭐⭐⭐⭐⭐ |
| Communication Services | -0.2% | -1.8% | +1.2% | 21.9 | 83/100⭐⭐⭐⭐⭐ |
| Energy | -0.2% | -6.1% | +1.5% | 37.0 | 75/100⭐⭐⭐⭐⭐ |
| Healthcare | -1.4% | -3.7% | -0.5% | 30.2 | 60/100⭐⭐⭐⭐ |
| Technology | -0.8% | -7.7% | +0.0% | 48.7 | 55/100⭐⭐⭐⭐ |
| Consumer Defensive | +0.7% | +3.0% | -1.6% | 31.1 | 50/100⭐⭐⭐ |
| Real Estate | -1.0% | -1.8% | -1.9% | 50.3 | 31/100⭐⭐ |
| Industrials | -2.7% | -7.6% | -2.1% | 41.5 | 30/100⭐⭐ |
| Basic Materials | -1.9% | -6.0% | -3.5% | 26.6 | 28/100⭐⭐ |
| Utilities | -2.1% | -6.9% | -8.5% | 25.3 | 24/100⭐ |
| Consumer Cyclical | -1.5% | -4.5% | -3.4% | 52.2 | 14/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score: 70% 1M momentum percentile + 30% valuation percentile (lower P/E ranks higher), shown as 0–100 with stars. Data as of 2026-06-11.